MarketBeat
22 Nov 2026, 05:12 UTC · 1h ago
Ardelyx Targets 2027 Profitability as IBSRELA Faces Insurance Hurdles
Impact · against what's priced in
ARDX is shifting from a pure growth story to a profitability timeline, establishing a clear target for GAAP positive EPS in 2027. While insurance headwinds and slowing growth for IBSRELA are already reflected in the valuation, the potential for a CIC indication in late 2027 provides a significant future catalyst to expand the addressable market.
- ARDX+0.30
No priced-in read yet
- In context
The commitment to GAAP profitability by 2027 and the Phase 3 timeline for the CIC indication (data H2 2027) provide concrete fundamental milestones not previously detailed. Conversely, the revised 30% growth rate and insurance frictions are already reflected in current guidance.





